Rat (Wistar) Liver CDAA Diet 4-8-12 Weeks Ensembl84 (BIBC)

Nonalcoholic steatohepatitis (NASH) is a major cause of liver fibrosis with increasing prevalence worldwide. Currently there are no approved drugs available. The development of new therapies is difficult as diagnosis and staging requires biopsies. Consequently, predictive plasma biomarkers would be useful for drug development. Here we present a multi-omics approach to characterize the molecular pathophysiology and to identify new plasma biomarkers in a choline-deficient L-amino acid-defined diet rat NASH model. We analyzed liver samples by RNA-Seq and proteomics, revealing disease relevant signatures and a high correlation between mRNA and protein changes. Comparison to human data showed an overlap of inflammatory, metabolic, and developmental pathways. 48 samples: two conditions (CDAA vs. CSAA diet) x three timepoints (4 weeks, 8 week, 12 weeks) x eight animals per group

非酒精性脂肪性肝炎（Nonalcoholic steatohepatitis, NASH）是全球患病率持续升高的肝纤维化主要病因，目前尚无获批上市的治疗药物。由于该病的诊断与分期需依赖肝脏活检，新疗法的研发难度极大。因此，具备预测价值的血浆生物标志物将对药物研发具有重要意义。本研究针对胆碱缺乏型L-氨基酸限定饲料（choline-deficient L-amino acid-defined diet）构建的大鼠NASH模型，采用多组学方法解析其分子病理生理学特征，并筛选新型血浆生物标志物。我们通过RNA测序（RNA-Seq）与蛋白质组学技术对肝脏样本进行分析，揭示了与疾病相关的分子特征，以及mRNA与蛋白表达变化之间的高度相关性。与人类相关数据集的对比分析显示，二者在炎症、代谢及发育通路方面存在显著重叠。本数据集共包含48份样本：2种饲料干预条件（胆碱缺乏型L-氨基酸限定饲料（CDAA）与胆碱充足型L-氨基酸限定饲料（CSAA）） × 3个时间节点（4周、8周、12周） × 每组8只实验动物。